During the last year, we have seen increased interest in the US cannabis industry and this a trend that we expect to continue. So far this year, there has been a significant increase in the number of public companies that are levered to the US market and we have been focused on the operators that represent leading opportunities.
2019 has been a banner year for the cannabis industry and we are not even halfway through the year. When it comes to the state of the cannabis industry in the US, it is no longer a question of if but when in regards to federal legalization. This would be a massive catalyst for the companies that are levered to the US cannabis industry and we are excited about this.
GreenStar Biosciences is a company that has attractive leverage to the US market and is an opportunity that we have been closely following. On Friday, the company will commence trading on the Canadian Stock Exchange (CSE) under the symbol, GSTR, and this is an opportunity to be watching. Today, we have issued an update on the burgeoning cannabis business and please reach out to firstname.lastname@example.org if you would like to learn more.
Greenstar is an Emerging Opportunity to be Watching
GreenStar Biosciences is planning a major expansion in 2019, and is planning on entering several states that include California, Oregon, Michigan, West Virgina, and Nevada. Initially, the company had been focused on the burgeoning cannabis market in Washington state. This was one of the first states to roll-out a recreational cannabis platform and we are favorable on the leverage to this market. When it comes to the Washington state cannabis market, GreenStar Biosciences has been successful and is a top 5 cannabis producer/processer in this market.
One of the ways that the company has been able to differentiate itself from the competition is though the implementation of state-of-the-art vertically integrated cultivation technologies and we find this to be significant. The focus on utilizing this type of technologies, the company has been able to significantly reduce expenses and can produce at a cost that is significantly lower than the industry standard.
GreenStar Biosciences has been sourcing premium cannabis from leading producers in the state and has been doing so at affordable prices. The company has developed a strategic network of leading retailers in Washington state and we are favorable on this aspect of the story. GreenStar Biosciences is the largest independent buyer of cannabis flower in Washington state and produces more than 200,000 pre-rolls on a monthly basis. This represents a massive opportunity and we are favorable on the ability to capitalize on a major vertical of the cannabis industry.
Has a Significant Opportunity and an Impressive Track Record
During the last year, GreenStar Biosciences has reported impressive growth and generated more than $3.5 million of revenue in the most recent quarter. This is a trend that we expect to continue and we are favorable on the growth prospects associated with the planned expansion.
GreenStar Biosciences represents a multi-faceted growth opportunity and we are favorable on the number of potential catalysts for growth. Currently, the company performs green extraction in facilities in Washington state, makes high-quality cannabis derivative products, packages and ships products to leading dispensaries, sources the best input product from leading cultivators to create best-in-class products, and utilizes proprietary methods and state-of-the-art technology to lower the average cost per gram
GreenStar Biosciences offers a suite of premium cannabis products and we are favorable on this leverage to the flower and derivative market. The company has been recording strong demand for its products and we want to highlight the brands that its owns:
- Hi Guys: Their products are offering as cannabis flower, pre-roll joints, and butane cannabis oil
- Dab Dudes: They specialize in butane cannabis oil, wax, vape cartridges, and crystalline.
- Cowlitz Gold: A premium cannabis brand that produces cannabis flower, pre-roll joints, butane cannabis oil, and vape cartridges
Levered to the Cannabis Infused Product Market
During the last year, we have seen a significant increase in the amount of demand for cannabis infused products. Many consumers are looking for standardized products that are accurately dosed and this is an area that GreenStar Biosciences has been focused on. Through the acquisition of Pharmastrip, the company is addressing this need and we are favorable on this aspect of the business.
Pharmastrip’s Cannabis Infused Oral Thin Film Strips are reliable and properly dosed cannabis infused strips that dissolve on your tongue. This acquisition makes Greenstar the global leader in delivering these organic cannabis strip products and we will monitor how the team is able to execute on this market. Pharmastrip has a proven track record of success and we are favorable on how Greenstar can enhance this business. Pharmastrip’s products have strong sell-through numbers and we believe that there is a significant licensing opportunity for the company.
Over the next year, we expect to see GreenStar Biosciences increase the number of states that it is selling products in and believe that this will be a major value driver for the overall business. By having a diverse product line that includes cannabis flower, oil and infused products, Greenstar has a significant opportunity license or to sell its products to dispensaries.
Generated more than $30 million in Revenue since Inception
In 2015, GreenStar Biosciences became operational and started selling products in April. The company has been nothing short of an execution story and has recorded strong growth since inception. In 2016, the company generated $6.58 million of revenue and grew this to $10.4 million in 2017. In 2018, Greenstar recorded further growth and generated almost $15 million in revenue.
So far this year, the company has recorded strong growth and we expect 2019 to be a banner year for the business. Greenstar is in the early innings of a major expansion and we are impressed with its ability to be successful in a highly competitive cannabis market. We are favorable on the expansion plans and believe that this will be a primary growth driver in the years ahead.
Another major potential value driver for GreenStar Biosciences pertains to the development of new cannabis products that target certain consumers and we are bullish on this. The company is focused on enhancing product verticals and broadening price points to attract new consumers. By focusing on the cannabis concentrate and flower opportunity, Greenstar has significant growth prospects and we are favorable on the focus on developing new products.
When it comes to the concentrate opportunity, GreenStar Biosciences is developing vape pens, cartridges, wax, tinctures, and capsules. When it comes to the flower opportunity, Greenstar has several brands (Columbia Valley Private Reserve, Cowlitz Creeper, Cowlitz Gold, and High Guy) and we are favorable on the diversity of this product line.
A Differentiated Growth Opportunity
GreenStar Biosciences represents a differentiated opportunity that is generating significant revenues and has attractive growth prospects. The company is led by a management team with a proven track record of success and we believe that this is one of the most important aspects of the entire story.
When it comes to investing in a cannabis company, you are really investing in the management team. We believe that GreenStar Biosciences is comprised of a management team that have diverse backgrounds and skill sets and we find this to be significantly. Most importantly, we believe that the management team is focused on creating value for shareholders and are favorable on the way that the team has advanced the story.
One of the ways that GreenStar Biosciences has differentiated itself from the competition is through the development of a patent pending “green” extraction process that uses water instead of other chemicals to create cannabis powder and waxes. We are favorable on this method and believe that creating differentiating factors like this is significant when it comes to standing out from the field of competitors.
Another way that GreenStar Biosciences has differentiated itself is through the formation of a joint partnership with Progressive Herbs Inc. Through this partnership, the company has an exclusive license on the intellectual property associated with the cultivation of cannabis. Greenstar has been laser focused on ensuring that it is using state-of-the-art cultivation technology to cultivate premium low-cost cannabis and this will play a major role in its success.
Some of the impacts that the use of this technology has includes the following:
- Increasing the total amount of production through a proprietary cultivation process
- Reducing the amount time to production by using the existing infrastructure which requires minimal modifications
- Finding efficiencies to reduce the amount labor while lowering utility expenses and water consumption
- Increasing the total yield while de-risking the operation with indoor hyper precision agriculture
A Burgeoning Cannabis Opportunity to be Watching
GreenStar Biosciences is a leading Washington state cannabis business that is planning a major expansion. The company has been developing a differentiated product portfolio that appeals to medical and recreational cannabis consumers. We are favorable on the continued success in the Washington state market and expect to see the company replicate its success in new markets.
Sine inception, GreenStar Biosciences has generated more than $30 million in revenue in Washington state and we are impressed with the growth on a year-over-year basis. This is a trend that we expect to continue and expect the overall company numbers to benefit from the planned expansion. If you look at a company like Halo Labs, you will see a company that initially started in Oregon and has since expanded into California and Oregon. In 2019, Halo Labs has been generating massive revenues and has been benefiting from its expansion into these additional markets.
We believe that GreenStar Biosciences could follow a similar trend and are favorable on the growth prospects associated with the markets that it is targeting. Over the next year, we expect to see the company significantly expand its reach and this is an opportunity to be monitoring. The management team has already proven itself to be a very capable operator and we are bullish on this aspect of the story.
GreenStar Biosciences represents an emerging cannabis opportunity and we will continue to monitor how the team continues to execute. To learn more about Greenstar, please email email@example.com.
Pursuant to an agreement between StoneBridge Partners LLC and GreenStar Biosciences we have been hired for a period of 90 days beginning May 28, 2019 and ending August 28, 2019 to publicly disseminate information about (GSTR) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (GSTR) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own two hundred thousand (200,000) shares of (GSTR), which we purchased via private placement. We plan to sell the “ZERO” shares of (GSTR) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (GSTR) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Published at Fri, 07 Jun 2019 11:28:18 +0000